ArticleBMC neurology2026
Anti-gad autoimmune encephalitis: a case report.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune encephalitis (AE) refers to a group of immune-mediated inflammatory disorders of the central nervous system. Though AE related to GAD antibodies is rare, its diagnosis is increasing due to heightened clinical awareness and improved serological testing. CASE PRESENTATION: We report a case of anti-GAD autoimmune encephalitis in a previously healthy 38-year-old male who presented with febrile illness followed by cognitive impairment, hallucinations, autonomic symptoms, and atypical seizures (manifesting as abdominal pain and persistent hiccups). Brain MRI was normal, but cerebrospinal fluid analysis showed lymphocytic pleocytosis, elevated protein, and a markedly increased opening pressure of 29 cm H₂O, consistent with intracranial hypertension. EEG demonstrated generalized background slowing without epileptiform discharges. Detection of anti-glutamic acid decarboxylase (GAD) antibodies confirmed the diagnosis. Immunotherapy with high-dose corticosteroids and rituximab led to full clinical resolution. At follow-up, the patient remained seizure-free and neurologically intact under maintenance rituximab therapy.
conclusionThis case underscores the importance of considering autoimmune encephalitis in patients with unexplained neuropsychiatric symptoms, even with normal imaging, and highlights the need for early immunomodulatory treatment to prevent long-term neurological sequelae and potential relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.